Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Res Treat
Prif Awduron: Kim, Seok-Jin, Hyeon, Jiyeon, Cho, Inju, Ko, Young Hyeh, Kim, Won Seog
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Korean Cancer Association 2019
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6473267/
https://ncbi.nlm.nih.gov/pubmed/30025443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.191
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg